Gene Modulation: A New Frontier for Neurodevelopmental Disorders

Dr. Xin Tang, who founded the Interventional Neurogenomics Laboratory at Boston Children's Hospital in 2021, presents the latest advances in gene modulation therapies for genetic neurodevelopmental disorders.

Unlike gene editing approaches that permanently alter DNA, gene modulation therapies aim to adjust how genes are expressed — turning them up or down to achieve therapeutic benefit. This approach is particularly promising for genetic conditions associated with autism, where specific gene variants contribute to neurodevelopmental differences.

Key areas of progress include: targeted gene expression modulation using advanced delivery systems; preclinical studies showing promise in specific genetic syndromes (such as Rett syndrome and Fragile X); and the development of more precise tools that can target specific brain regions.

Supported by the Simons Foundation Autism Research Initiative and the Hood Foundation, Dr. Tang's work represents the intersection of neurosurgery, genomics, and developmental neuroscience. While these therapies are still in research stages, they offer hope for individuals with specific genetic neurodevelopmental conditions.

Important context: Gene modulation research focuses on specific genetic conditions where a clear genetic mechanism is identified. This is distinct from autism broadly, which involves complex genetic and environmental interactions. These approaches are not about 'curing' autism but about addressing specific genetic conditions that may include autistic features.